Dear colleagues,
Chronic kidney disease (CKD) poses a significant and rapidly growing global health burden, with hypertension recognized as both a leading cause and the most impactful modifiable risk factor for CKD progression. A recent survey conducted among ESH Excellence Centres revealed notable gaps in CKD screening and management in European patients with hypertension—highlighting an urgent need for action.
Deepen your understanding of the optimal management of patients with hypertension and CKD by exploring the latest insights from the 2024 ESH Clinical Practice Guidelines for the Management of Arterial Hypertension.
If you missed the webinar, you can now access HERE the full recording, along with our experts’ answers to the questions raised during the live session.
Don’t miss this opportunity to enhance your expertise and advance the quality of care you provide to your patients.
You may also watch the individual lectures separately here:
INTRODUCTION
Reinhold Kreutz (Germany)
MEASURE BP –DIAGNOSE AND ASSESS PATIENT
BP measurements including ABPM, and the role of measuring uACR
Lene Halvorsen (Norway)
SELECT THERAPY
BP treatment in patients with CKD including SGLT2i and nsMRA
Pantelis Sarafidis (Greece)
EVALUATE RESPONSE
Evaluation and consideration during the initiation phase, short-term and long-term follow up
Liffert Vogt (The Netherlands)